Pharmadrug Inc. (LMLLF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.46: the stock has moved about 54% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPharmadrug Inc. (LMLLF) trades at $0.0045. Pharmadrug Inc. is a specialty pharmaceutical company focused on the research, development, and commercialization of controlled substances and natural medicines. Sector: Healthcare.
Price as of · Last analyzed: Mar 15, 2026Analyst Coverage for LMLLF: LMLLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Pharmadrug Inc. (LMLLF) Healthcare & Pipeline Overview
Pharmadrug Inc. is a specialty pharmaceutical company focusing on the research, development, and commercialization of controlled substances and natural medicines, including psychedelics and cannabis. The company imports medical cannabis to the EU and researches natural medicines, positioning itself within the evolving landscape of alternative therapies.
What Is the Investment Thesis for LMLLF?
Pharmadrug Inc. presents a speculative investment opportunity within the emerging market for psychedelic and cannabis-based pharmaceuticals. The company's research agreements with the University of Michigan and Johns Hopkins University, focusing on DMT, represent potential catalysts for future growth. The company's distribution of medical cannabis in Germany and the EU provides an existing revenue stream, though the company's market capitalization of $0.00B indicates significant risk. A P/E ratio of -4.44 reflects current losses, suggesting the company is in a high-growth, pre-profitability phase. The company's beta of 0.46 suggests lower volatility than the overall market. Success hinges on the clinical trial outcomes, regulatory approvals, and market acceptance of its products.
Based on FMP financials and quantitative analysis
LMLLF Key Highlights
Pharmadrug Inc. focuses on the research, development, and commercialization of controlled substances and natural medicines, including psychedelics and cannabis.
- The company imports and distributes medical cannabis to pharmacies in Germany and the rest of the European Union, providing an established revenue stream.
- Pharmadrug has a research agreement with the University of Michigan to evaluate N, N-dimethyltryptamine's (DMT) potential role in normal, diseased, and altered states of consciousness.
- The company has a clinical trial agreement with Johns Hopkins University to conduct a clinical study comparing the effects of DMT.
- Pharmadrug operates with a team of 9 employees, reflecting its focus on research and development.
Who Are LMLLF's Competitors?
LMLLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BIOE Bio Essence Corporation | $0.47 | 0.00% | $25.3M | — |
| SXTC China SXT Pharmaceuticals, Inc. | $2.59 | -8.48% | — | |
| YCBD cbdMD, Inc. | $0.38 | +1.42% | $5.10M | — |
| AKAN Akanda Corp. | $3.43 | -14.89% | $9.05M | — |
| QNTM Quantum BioPharma Ltd. | $1.42 | -6.58% | $9.13M | 30 5-pillar |
| BFRI Biofrontera Inc. | $0.60 | +1.10% | $10.8M | — |
| COSM COSM | $2.87 | -2.71% | $14.4M | — |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. | $3.90 | +2.01% | $18.6M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LMLLF's Key Strengths?
Focus on emerging markets such as psychedelics and medical cannabis.
- Research agreements with reputable universities and research institutions.
- Established distribution network for medical cannabis in Europe.
- Proprietary research and development capabilities.
What Are LMLLF's Weaknesses?
Limited financial resources and small market capitalization.
- Reliance on regulatory approvals and clinical trial outcomes.
- Limited number of employees.
- Negative P/E ratio indicates unprofitability.
What Are the Key Risks for LMLLF?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for DMT-based therapies.
- Changes in regulations regarding cannabis and psychedelics.
- Competition from larger pharmaceutical companies.
- Limited financial resources and reliance on external funding.
- Dependence on key personnel and research agreements.
What Are LMLLF's Competitive Advantages?
- Proprietary research and development capabilities in the area of controlled substances and natural medicines.
- Established distribution network for medical cannabis in Germany and the EU.
- Strategic partnerships with leading universities and research institutions.
- Focus on innovative therapies and emerging markets, such as psychedelics.
What Does LMLLF Do?
Pharmadrug Inc., formerly known as Aura Health Inc., was rebranded in October 2019 to reflect its strategic shift towards specialty pharmaceuticals. The company focuses on the research, development, and commercialization of controlled substances and natural medicines, including psychedelics, cannabis, and naturally-derived approved drugs. Pharmadrug imports and distributes medical cannabis to pharmacies in Germany and the rest of the European Union, capitalizing on the growing acceptance and legalization of cannabis for medical purposes. The company also owns and operates Super Smart, an entity focused on elevating the use of functional and psilocybin mushrooms. Pharmadrug is actively involved in researching and reformulating established natural medicines, seeking to identify new applications and improve existing treatments. The company has a research agreement with the University of Michigan to evaluate N, N-dimethyltryptamine's (DMT) potential role in normal, diseased, and altered states of consciousness. Additionally, Pharmadrug has an agreement with Southwest Research Institute for initiating non-clinical and clinical manufacturing of cepharanthine and a clinical trial agreement with Johns Hopkins University to conduct a clinical study comparing acute and enduring psychological and neural effects of DMT and an undisclosed potently active comparator molecule. Based in Toronto, Canada, Pharmadrug operates with a team of 9 employees, reflecting its focus on research and development activities.
What Products and Services Does LMLLF Offer?
- Researches and develops controlled substances and natural medicines.
- Focuses on psychedelics, cannabis, and naturally-derived approved drugs.
- Imports and distributes medical cannabis to pharmacies in Germany and the EU.
- Operates Super Smart, focused on functional and psilocybin mushrooms.
- Researches and reformulates established natural medicines.
- Conducts clinical trials to evaluate the effects of DMT.
How Does LMLLF Make Money?
- Generates revenue through the import and distribution of medical cannabis.
- Develops and commercializes novel pharmaceutical products based on controlled substances and natural medicines.
- Conducts research and development activities under agreements with universities and research institutions.
- Operates Super Smart, focused on functional and psilocybin mushrooms.
What Industry Does LMLLF Operate In?
Pharmadrug Inc. operates within the specialty pharmaceutical and emerging psychedelic medicine industries. These sectors are characterized by rapid innovation, evolving regulatory landscapes, and increasing interest in alternative therapies. Pharmadrug competes with other specialty pharmaceutical companies and firms focused on psychedelic research and development. Competitors include BIOE, CNGGF, CPMD, NRPR, and RAFA. Success in this industry requires strong research capabilities, regulatory expertise, and effective commercialization strategies.
Who Are LMLLF's Key Customers?
- Pharmacies in Germany and the rest of the European Union that distribute medical cannabis.
- Patients who use medical cannabis and other pharmaceutical products developed by the company.
- Consumers interested in functional and psilocybin mushroom products through Super Smart.
- Research institutions and universities that collaborate with Pharmadrug on research and development projects.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Pharmadrug Inc. stands at 38.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -85.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -13.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -95.5%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Pharmadrug Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO David Kideckel. LMLLF has traded publicly since 2017.
Financial Health
Pharmadrug Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
LMLLF Latest News
No recent news available for LMLLF.
LMLLF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LMLLF.
Price Targets
Wall Street price target analysis for LMLLF.
LMLLF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LMLLF; grades run from A+ (80-100) to F (below 30).
Leadership: David Kideckel
CEO
David Kideckel serves as the CEO of Pharmadrug Inc., leading a team of 9 employees. His background includes experience in the healthcare and pharmaceutical industries. He has a track record of working with emerging companies in the life sciences sector. His expertise spans strategic planning, business development, and capital markets. Kideckel's leadership is focused on driving Pharmadrug's research and development efforts and expanding its market presence.
Track Record: Under David Kideckel's leadership, Pharmadrug Inc. has focused on research agreements with the University of Michigan and Johns Hopkins University. He has overseen the company's efforts to develop novel therapies based on controlled substances and natural medicines. He has also guided the company's expansion in the European medical cannabis market. His strategic decisions have positioned Pharmadrug in the emerging psychedelic medicine industry.
LMLLF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Pharmadrug Inc. may not meet the minimum financial standards or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for low trading volume and liquidity.
- Higher risk of fraud and manipulation compared to listed exchanges.
- Limited regulatory oversight and investor protection.
- Increased price volatility due to speculative trading.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capitalization structure and potential dilution.
- Review the company's legal and regulatory compliance.
- Monitor news and press releases for any red flags or material events.
- Consult with a qualified financial advisor.
- Research agreements with reputable universities such as the University of Michigan and Johns Hopkins University.
- Focus on research and development of pharmaceutical products.
- Established distribution network for medical cannabis in Europe.
- Active participation in industry conferences and events.
- Presence of experienced management team with backgrounds in healthcare and pharmaceuticals.
What Investors Ask About Pharmadrug Inc. (LMLLF) — Healthcare
What do analysts say about LMLLF stock?
Given its OTC listing and focus on emerging markets like psychedelics and medical cannabis, analyst coverage may be limited. Investors should conduct their own due diligence and carefully evaluate the company's financial condition, research pipeline, and regulatory risks. Key valuation metrics include market capitalization, revenue growth, and cash flow. The speculative nature of the business warrants a cautious approach.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.